高剂量与低剂量地塞米松对住院中重度COVID-19肺炎患者临床恶化的影响:一项开放标签随机临床试验
本研究为随机开放标签对照试验,纳入200例需氧疗的住院COVID-19肺炎患者,比较低剂量地塞米松(6 mg每日一次共10天)与高剂量方案(20 mg每日一次共5天,后10 mg每日一次共5天)。主要终点为随机化后11天内临床恶化,高剂量组发生率16.3%显著低于低剂量组31.4%(率比0.427,95%CI 0.216-0.842;P=0.014)。28天死亡率两组无显著差异(5.9% vs 6.1%,P=0.844),恢复时间及第5、11、14、28天七分类量表评分亦无显著差异。
要点
- 高剂量地塞米松较地塞米松6 mg每日一次显著降低11天内临床恶化风险。
- 高剂量与低剂量组28天死亡率无显著差异(5.9% vs 6.1%,P=0.844)。
- 恢复时间及第5、11、14、28天临床状态量表评分两组无显著差异。
核心结论
- 在需氧疗的住院COVID-19肺炎患者中,高剂量地塞米松较低剂量减少随机化后11天内的临床恶化。
研究设计与样本
- 随机、开放标签、对照试验,纳入200例确诊COVID-19肺炎且需氧疗的住院患者。
- 患者按1:1随机分配接受低剂量地塞米松(6 mg每日一次共10天)或高剂量地塞米松(20 mg每日一次共5天,后10 mg每日一次共5天)。
- 主要终点为随机化后11天内临床恶化;次要终点包括28天死亡率、恢复时间及第5、11、14、28天七分类量表临床状态。
主要发现
- 低剂量组102例中32例(31.4%)出现11天内临床恶化,高剂量组98例中16例(16.3%)出现(率比0.427,95%CI 0.216-0.842;P=0.014)。
- 28天死亡率低剂量组为5.9%,高剂量组为6.1%(P=0.844)。
- 恢复时间及第5、11、14、28天七分类量表评分两组无显著差异。
关键数值与推荐
- 低剂量地塞米松方案:6 mg每日一次,共10天。
- 高剂量地塞米松方案:20 mg每日一次共5天,随后10 mg每日一次共5天。
- 主要终点率比0.427(95%CI 0.216-0.842;P=0.014),28天死亡率组间P=0.844。
临床怎么用
- 对于需氧疗的住院中重度COVID-19肺炎患者,可考虑高剂量地塞米松以降低短期临床恶化风险。
- 高剂量方案未显示28天死亡率获益,临床决策需结合患者个体情况权衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Low-dose dexamethasone demonstrated clinical improvement in patients with coronavirus disease 2019 (COVID-19) needing oxygen therapy; however, evidence on the efficacy of high-dose dexamethasone is limited. METHODS: We performed a randomised, open-label, controlled trial involving hospitalised patients with confirmed COVID-19 pneumonia needing oxygen therapy. Patients were randomly assigned in a 1:1 ratio to receive low-dose dexamethasone (6 mg once daily for 10 days) or high-dose dexamethasone (20 mg once daily for 5 days, followed by 10 mg once daily for an additional 5 days). The primary outcome was clinical worsening within 11 days since randomisation. Secondary outcomes included 28-day mortality, time to recovery and clinical status at day 5, 11, 14 and 28 on an ordinal scale ranging from 1 (discharged) to 7 (death). RESULTS: A total of 200 patients (mean±sd age 64±14 years; 62% male) were enrolled. 32 (31.4%) out of 102 patients enrolled in the low-dose group and 16 (16.3%) out of 98 in the high-dose group showed clinical worsening within 11 days since randomisation (rate ratio 0.427, 95% CI 0.216-0.842; p=0.014). The 28-day mortality was 5.9% in the low-dose group and 6.1% in the high-dose group (p=0.844). There was no significant difference in time to recovery, and in the seven-point ordinal scale at days 5, 11, 14 and 28. CONCLUSIONS: Among hospitalised COVID-19 patients needing oxygen therapy, high dose of dexamethasone reduced clinical worsening within 11 days after randomisation, compared with low dose.
引用
- Taboada M, Rodríguez N, Varela PM, et al. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial. Eur Respir J. 2022. PMID: 34916266. doi:10.1183/13993003.02518-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。